Literature DB >> 15352538

New options in the pharmacological management of attention-deficit/hyperactivity disorder.

Mark Olfson.   

Abstract

A brief review of the efficacy and common side effects of pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD) is presented. Methylphenidate and amphetamine continue to have the strongest base of empiric support. They are both available in extended- and immediate-release preparations. Although most children with ADHD respond favorably to either medication, many children who do not respond to one medication will respond to the other. Additional pharmacological options include the nonstimulant atomoxetine, the stimulant pemoline, the antidepressants bupropion and desipramine, and the antihypertensives clonidine and guanfacine. In selecting the appropriate pharmacological regimen, consideration should be given to the child's daily school and after-school schedule, the presence of aggressive symptoms, and the risk of diversion. Careful selection of an appropriate medication regimen and active engagement of the child, parents, and teacher in daily management may help to ensure long-term adherence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15352538

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  5 in total

1.  Combination and switching of stimulants in children and adolescents with attention deficit/hyperactivity disorder in quebec.

Authors:  Leila Ben Amor; Vanja Sikirica; Martin Cloutier; Jean Lachaine; Annie Guerin; Valerie Carter; Paul Hodgkins; Judy van Stralen
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2014-09

2.  A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy.

Authors:  Minji Sohn; Jeffery Talbert; Daniela C Moga; Karen Blumenschein
Journal:  Atten Defic Hyperact Disord       Date:  2016-05-03

Review 3.  Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions.

Authors:  Grazia Dell'Agnello; Alessandro Zuddas; Gabriele Masi; Paolo Curatolo; Dante Besana; Andrea Rossi
Journal:  CNS Drugs       Date:  2009-09       Impact factor: 5.749

4.  Concomitant pharmacotherapy of psychotropic medications in EU children and adolescents with attention-deficit/hyperactivity disorder.

Authors:  Vanja Sikirica; Moshe Fridman; Amanda Bruno; Paul Hodgkins; M Haim Erder
Journal:  Drugs R D       Date:  2013-12

5.  Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States.

Authors:  Zhou Zhou; Keith A Betts; Iryna Bocharova; David Kinrich; William M Spalding
Journal:  J Atten Disord       Date:  2018-07-10       Impact factor: 3.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.